- Top of page
- Timing of Acute Interventional Therapy in Non–ST-Elevation Myocardial Infarction
- Timing, Duration, and Application of Dual and Triple Antiplatelet Therapy
- Recommendations for Diabetes Mellitus
- Role and Potential Benefit of Invasive Therapies in Patients With Advanced Renal Dysfunction
- Quality Improvement for Acute Coronary Syndromes
- Post–Guideline-Update Relevant Acute Coronary Syndrome Trials
- US Food and Drug Administration Drug Approval Subsequent to the Guideline Update
The 2011 Update to the Unstable Angina/Non–ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline is based in evolving data or expert opinion and incorporates information from late-breaking clinical trials presented at the 2008–2009 Scientific Sessions of the American College of Cardiology, the American Heart Association, and the European Society of Cardiology, among others, as well as selected data through April 2010.
The 5 key issues highlighted in this summary are: (1) the timing of acute interventional therapy in non–ST-elevation myocardial infarction; (2) emphasis on the timing, duration, and application of dual and triple antiplatelet therapy; (3) specific recommendations for patients with diabetes mellitus; (4) the role and potential benefit of invasive therapy in patients with advanced renal dysfunction; and (5) issues of quality improvement for acute coronary syndromes. © 2011 Wiley Periodicals, Inc.
Dr. Wenger is a consultant at Emory Heart and Vascular Center, Atlanta, Georgia. The author has no other funding, financial relationships, or conflicts of interest to disclose.